NYSE:NVTA

Invitae Stock Forecast, Price & News

$27.40
+0.30 (+1.11 %)
(As of 07/28/2021 12:00 AM ET)
Add
Compare
Today's Range
$27.40
$27.40
50-Day Range
$26.85
$34.47
52-Week Range
$25.24
$61.59
Volume10 shs
Average Volume4.02 million shs
Market Capitalization$5.48 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.9
30 days | 90 days | 365 days | Advanced Chart
Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.


Invitae logo

About Invitae

Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.97 out of 5 stars

Medical Sector

188th out of 2,218 stocks

Medical Laboratories Industry

4th out of 41 stocks

Analyst Opinion: 4.3Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Invitae (NYSE:NVTA) Frequently Asked Questions

Is Invitae a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Invitae stock.
View analyst ratings for Invitae
or view top-rated stocks.

What stocks does MarketBeat like better than Invitae?

Wall Street analysts have given Invitae a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Invitae wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Invitae?

Invitae saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 26,850,000 shares, a decrease of 15.3% from the June 30th total of 31,700,000 shares. Based on an average trading volume of 3,500,000 shares, the days-to-cover ratio is presently 7.7 days. Currently, 13.6% of the shares of the stock are sold short.
View Invitae's Short Interest
.

When is Invitae's next earnings date?

Invitae is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Invitae
.

How can I listen to Invitae's earnings call?

Invitae will be holding an earnings conference call on Tuesday, August 3rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) posted its earnings results on Tuesday, May, 4th. The medical research company reported ($0.63) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.03. The medical research company earned $103.60 million during the quarter, compared to analyst estimates of $101.46 million. Invitae had a negative net margin of 194.99% and a negative trailing twelve-month return on equity of 31.82%. Invitae's revenue for the quarter was up 61.2% compared to the same quarter last year. During the same period last year, the firm posted ($1.03) EPS.
View Invitae's earnings history
.

How has Invitae's stock price been impacted by Coronavirus (COVID-19)?

Invitae's stock was trading at $15.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVTA shares have increased by 71.0% and is now trading at $27.10.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NVTA?

8 brokerages have issued twelve-month price objectives for Invitae's shares. Their forecasts range from $33.00 to $58.00. On average, they expect Invitae's stock price to reach $43.38 in the next year. This suggests a possible upside of 60.1% from the stock's current price.
View analysts' price targets for Invitae
or view top-rated stocks among Wall Street analysts.

Who are Invitae's key executives?

Invitae's management team includes the following people:
  • Dr. Sean Emerson George, Co-Founder, Pres, CEO & Director (Age 47, Pay $451.35k)
  • Mr. Kenneth D. Knight, Chief Operating Officer (Age 60, Pay $428.5k)
  • Mr. Thomas R. Brida, Gen. Counsel, Chief Compliance Officer & Sec. (Age 50, Pay $348.75k)
  • Mr. Lee Bendekgey, Chief Policy Officer (Age 63, Pay $383.64k)
  • Mr. Alex Furman, Co-Founder, Culture Tsar & Head of People Analytics
  • Ms. Michele Cargill Ph.D., Co-Founder, Key Projects & Advisor to the CEO
  • Ms. Yafei Wen, Chief Financial Officer (Age 49)
  • Mr. Robert F. Werner, Chief Accounting Officer & Principal Accounting Officer (Age 48)
  • Mr. Layton Wedgeworth, Chief Technology Officer
  • Ms. Laura D'Angelo, Head of Investor Relations

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae CEO Sean George on Glassdoor.com. Sean George has an approval rating of 87% among Invitae's employees.

Who are some of Invitae's key competitors?

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), The Trade Desk (TTD), Shopify (SHOP), salesforce.com (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by many different retail and institutional investors. Top institutional investors include Harel Insurance Investments & Financial Services Ltd. (0.01%), Boyd Watterson Asset Management LLC OH (0.00%) and Compagnie Lombard Odier SCmA (0.00%). Company insiders that own Invitae stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Randal W Scott, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for Invitae
.

Which major investors are selling Invitae stock?

NVTA stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, Harel Insurance Investments & Financial Services Ltd., and Boyd Watterson Asset Management LLC OH. Company insiders that have sold Invitae company stock in the last year include Artur Bergman, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for Invitae
or view top insider-selling stocks.

How do I buy shares of Invitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $27.10.

How much money does Invitae make?

Invitae has a market capitalization of $5.42 billion and generates $279.60 million in revenue each year. The medical research company earns $-602,170,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis.

How many employees does Invitae have?

Invitae employs 2,100 workers across the globe.

What is Invitae's official website?

The official website for Invitae is www.invitae.com.

Where are Invitae's headquarters?

Invitae is headquartered at 1400 16th Street, SAN FRANCISCO CA, 94103.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.